Abstract
Background The off-label use of drugs to treat children is a global practice attributed to the traditional exclusion of children from clinical trials mainly due to practical and ethical reasons. Off-label drug use carries both benefits and risks, but data regarding this use pattern are scanty in sub-Saharan Africa. Objective To determine the incidence and predictors of off-label antibiotic use in children less than 5 years admitted at Mbarara Regional Referral Hospital (MRRH) in southwestern Uganda. Setting A prospective drug utilisation study was conducted among in-patients at the Paediatric Ward of MRRH from May to June 2019. Methods Clinical records and treatment notes of all children aged 0 to 59 months with at least one antibiotic prescription during the admission period were reviewed and included for data collection. Key informant interviews were conducted with physicians attending to patients in the Paediatric Ward. Main outcome measure Off-label use and potential predictors of off-label antibiotic use. Results Of 427 children admitted to the Paediatric Ward, 165 (38.6%) received 366 antibiotic prescriptions. However, 359 prescriptions belonging to 162 patients were analyzed. Off-label prescriptions occurred in 18.9% (95% CI: 14.9–23.0) of antibiotic prescriptions. Two categories of off-label prescriptions were found: off-label frequency of administration (n = 55, 80.9%), and off-label doses (n = 13, 19.1%). Ceftriaxone was the most common antibiotic prescribed at off-label doses, (n = 6, 8.8%) while ampicillin was the most common antibiotic prescribed with an off-label frequency of administration, (n = 39, 57.3%). Infants (1–23 months) received the majority (47.1%) of off-label antibiotic prescriptions; neonates (0–28 days) received 27.9%, and children (24–59 months) received 25% of the prescriptions. Controlling for sex and disease severity, age category remained significantly associated with off-label antibiotic use on multivariate analysis. Conclusion Off-label frequency of administration was the major category of off-label drug use, while off-label dose was the minor category. Age was a significant factor for off-label antibiotic prescription, with infants receiving the highest number of off-label prescriptions. Attending physicians identified several justifiable circumstances that warrant off-label antibiotic use and support emerging “well-founded” off-label uses of antibiotics in different paediatric age groups.
Similar content being viewed by others
References
Golombek SG, van den Anker J, Rose K. Clinical trials in children. Int J Pharm Med. 2007;21:121–9.
Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79:357–69.
Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91:796–801.
Zingg W, Posfay-Barbe MK. Antibiotic use in children-off-label use. Curr Drug Targets. 2012;13:885–92.
Joret-Descout P, Prot-Labarthe S, Brion F, Bataille J, Hartmann J-F, Bourdon O. Off-label and unlicensed utilisation of medicines in a French paediatric hospital. Int J Clin Pharm. 2015;37:1222–7.
Mukattash TL, Hayajneh WA, Ibrahim SM, Ayoub A, Ayoub N, Jarab AS, et al. Prevalence and nature of off-label antibiotic prescribing for children in a tertiary setting: a descriptive study from Jordan. Pharm Pract Granada. 2016;14:725.
Uganda National Drug Authority. Guidelines on submission of documentation for marketing authorisation of a pharmaceutical product for human use. 2018.
Parliament of Uganda. National drug policy and authority act. Uganda. 1993.
Neville KA, Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Paul IM, et al. Off-label use of drugs in children. Pediatrics. 2014;133:563–7.
Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med. 2008;358:1427–9.
Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665.
Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004;27:1059–67.
Kruger M, Makiwane MM, Ramoroka S, van Elsland SL, Lawrence K, Rosenkranz B. Off-label use in ambulatory paediatric clinics in a Central South African Hospital. J Trop Pediatr. 2018.
Okechukwu RC, Aghom O. Prescription pattern of unlicensed and off-label medicines for children aged 0-5 years in a tertiary hospital and a primary health care centre in Nigeria. South Afr J Bioeth Law. 2009;2:2.
Oshikoya KA, Oreagba IA, Godman B, Fadare J, Orubu S, Massele A, et al. Off-label prescribing for children with chronic diseases in Nigeria; findings and implications. Expert Opin Drug Saf. 2017;16:981–8.
Tefera YG, Gebresillassie BM, Mekuria AB, Abebe TB, Erku DA, Seid N, et al. Off‐label drug use in hospitalized children: a prospective observational study at Gondar University Referral Hospital, Northwestern Ethiopia. Pharmacol Res Perspect 5. 2017.
Hannsjorg WS, Anders R, Matthias S. Pediatric clinical pharmacology: handbook of experimental pharmacology. Berlin: Springer; 2011. XII. 384 p, ISBN: 978-3-642-20194-3.
World Health Organization. Hospital care for children: guidelines for management of common childhood illnesses. 2nd ed. Geneva: Switzerland; 2013.
Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Int Med. 2012;172:781–8.
Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11:32.
Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharm. 2009;48:143–57.
Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18:59–82.
Galvin R. How many interviews are enough? Do qualitative interviews in building energy consumption research produce reliable knowledge? J Build Eng. 2015;1:2–12.
Priest H, Roberts P, Woods L. An overview of three different approaches to the interpretation of qualitative data. Part 1: theoretical issues. Nurse Res. 2002;10:30–42.
Tansarli GS, Rafailidis PI, Kapaskelis A, Falagas ME. Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Rev Anti infect Ther. 2012;10:1383–92.
Porta A, Esposito S, Menson E, Spyridis N, Tsolia M, Sharland M, et al. Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol. 2010;66:919–27.
Santos DB, Clavenna A, Bonati M, Coelho HLL. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol. 2008;64:1111.
W’t Jong G, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics. 2001;108:1089–93.
Gijsen R, Jochemsen H, van Dijk L, Caspers P. Frequency of ill-founded off-label prescribing in Dutch general practice. Pharmacoepidemiol Drug Saf. 2009;18:84–91.
Acknowledgements
We thank Dr. Elias Kumbakumba, Head of Paediatrics and Child Health, Mbarara University of Science and Technology, for his technical guidance during the research. We gratefully acknowledge Associate Prof. Joan Nakayaga Kalyango, Clinical Epidemiology Unit, College of Health Sciences, Makerere University for the administration of Project 346.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was supported by Sida Phase IV bilateral support to Makerere University Research SE-0-SE-6-5118006001-UGA-43082, Project Code: 346-2014.
Conflicts of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Obura, B., Alele, P.E. & Obua, C. Off-label antibiotic use among paediatric in-patients: a mixed-method prospective study at a tertiary hospital in southwestern Uganda. Int J Clin Pharm 43, 637–644 (2021). https://doi.org/10.1007/s11096-020-01175-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-020-01175-1